project-idea

PedBrainTarget: A Drug-Target Interaction Tracker for Pediatric Brain Cancer Stem Cell Pathways

A REST-AKT-SOX2 regulatory axis maintains therapy-resistant stem/progenitor cells in Sonic Hedgehog medulloblastoma — and both AKT inhibitors and Midkine inhibitors with clinical-stage compounds already exist.

Pediatric brain tumors are difficult to treat partly because of the disconnect between adult oncology drug development (where most AKT, SOX2, and Midkine inhibitor trials are run) and pediatric-specific tumor biology. PedBrainTarget would be a curated tracker mapping known druggable targets in pediatric brain cancer stem cell pathways to the current status of clinical-stage inhibitors.

For each target (AKT, REST, SOX2, Midkine, and related pathway members), the tracker would show: what preclinical evidence exists for this target in pediatric brain tumors, which clinical-stage compounds are available, what pediatric clinical trials (if any) have been run, and what safety profile is established in children. The REST-AKT-SOX2 axis from this paper would be one entry; the broader database would cover all well-characterized pediatric brain tumor stem cell pathways.

The tool would automatically update from ClinicalTrials.gov and publish a monthly 'what's new' digest to a subscriber list — researchers, pediatric oncologists, and patient advocates — summarizing new trial registrations, completed studies, and newly published target validations. This keeps a small but important community current on a rapidly evolving field.

Who Is This For?

Pediatric oncology researchers, pediatric neuro-oncologists, and parent/patient advocacy groups working on medulloblastoma and other childhood brain tumors.

Skills & Tools Needed

ClinicalTrials.gov API and literature database integration
Web development
Oncology knowledge (especially pediatric brain tumors)
Automated newsletter/digest generation
Data curation methodology

Feasibility

medium — The curated database component requires sustained expert effort, but the technical stack is straightforward; automated ClinicalTrials.gov updates reduce ongoing maintenance burden.

Inspired by: REST-AKT-SOX2 axis controls neuronal lineage state and Midkine-mediated communication in SHH-medulloblastoma.

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.